Home  »  Companies   »  Who is the Top Investor In Revance Therapeutics In...

Who is the Top Investor In Revance Therapeutics Inc. (RVNC)?

Revance Therapeutics Inc. (NASDAQ: RVNC) is 66.90% higher on its value in year-to-date trading and has touched a low of $11.27 and a high of $37.98 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The RVNC stock was last observed hovering at around $31.51 in the last trading session, with the day’s loss setting it -0.7% off its average median price target of $40.00 for the next 12 months. It is also 52.6% off the consensus price target high of $65.00 offered by 13 analysts, but current levels are -46.71% lower than the price target low of $21.00 for the same period.

Currently trading at $30.81, the stock is -8.10% and -5.11% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.8 million and changing -2.22% at the moment leaves the stock 12.68% off its SMA200. RVNC registered 140.70% gain for a year compared to 6-month gain of 35.85%. The firm has a 50-day simple moving average (SMA 50) of $19.91 and a 200-day simple moving average (SMA200) of -$11.62.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.


The stock witnessed a -2.22% loss in the last 1 month and extending the period to 3 months gives it a -9.70%, and is -3.17% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 4.37% over the week and 5.07% over the month.

Revance Therapeutics Inc. (RVNC) has around 534 employees, a market worth around $2.59B and $156.60M in sales. Distance from 52-week low is 173.38% and -18.88% from its 52-week high. The company has generated returns on investments over the last 12 months (-87.30%).

Revance Therapeutics Inc. (RVNC) Analyst Forecasts

Analyst recommendations provided by FactSet shows that the consensus forecast for Revance Therapeutics Inc. (RVNC) is a “Overweight”. 13 analysts offering their recommendations for the stock have an average rating of 2.10, where 2 rate it as a Hold and 1 think it is a “Overweight”. 9 of the analysts rate the stock as a “Buy”. 1 analysts have rated the stock as a Sell or Underperform.

Revance Therapeutics Inc. is expected to release its quarterly report on 08/09/2023.The EPS is expected to shrink by -17.60% this year

Revance Therapeutics Inc. (RVNC) Top Institutional Holders

The shares outstanding are 81.13M, and float is at 79.47M with Short Float at 18.52%.

Revance Therapeutics Inc. (RVNC) Insider Activity

A total of 24 insider transactions have happened at Revance Therapeutics Inc. (RVNC) in the last six months, with sales accounting for 20 and purchases happening 4 times. The most recent transaction is an insider sale by Foley Mark J, the company’s CEO. SEC filings show that Foley Mark J sold 70,447 shares of the company’s common stock on May 15 at a price of $34.55 per share for a total of $2.43 million. Following the sale, the insider now owns 0.92 million shares.

Revance Therapeutics Inc. disclosed in a document filed with the SEC on May 15 that Schilke Tobin (CFO) sold a total of 21,401 shares of the company’s common stock. The trade occurred on May 15 and was made at $34.55 per share for $0.74 million. Following the transaction, the insider now directly holds 84029.0 shares of the RVNC stock.

Still, SEC filings show that on May 15, Moxie Dwight (SVP, GC & Secretary) disposed off 21,401 shares at an average price of $34.55 for $0.74 million. The insider now directly holds 69,165 shares of Revance Therapeutics Inc. (RVNC).

Revance Therapeutics Inc. (RVNC): Who are the competitors?

The company’s main competitors (and peers) include Ionis Pharmaceuticals Inc. (IONS) that is trading 5.55% up over the past 12 months and Biogen Inc. (BIIB) that is 46.70% higher over the same period. Johnson & Johnson (JNJ) is -14.88% down on the 1-year trading charts.

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts